Name: ALPROSTADIL (Prostaglandin E1, Prostin VRR)
Classification: arterial vasodilator; platelet-aggregation inhibitor
  • used in ischemic conditions to dilate small vessels (eg. Raynaud's disease, peripheral vascular disease)
  • 5-30 ng/kg/min, titrated to patient response

IV Infusion:
500 ug / 100 ml NS (5 ug/ml)

Adverse Effects:
  • hypotension
  • tachycardia
  • bleeding
Monitoring Therapy:
  • cutaneous vasodilation (sign of misplacement of infusion line)
  • arterial pressure, HR
  • peripheral perfusion
CCTC Protocol:
  • May be administered by IV infusion by an approved RN in CCTC.
  • Must be administered via a central line.
  • Continuous infusion requires the use of an infusion pump.
Last Update: April 28, 2006

Lynne Kelly, Pharmacist, CCTC
Brenda Morgan, Clinical Nurse Specialist, CCTC
Last Update: August 7, 2006

LHSCHealth Professionals

Last Updated March 24, 2009 | © 2007, LHSC, London Ontario Canada